The global fusion proteins market is on track for substantial growth, with projections indicating an increase from $36.3 billion in 2025 to approximately $64.9 billion by the end of 2030. This represents a compound annual growth rate (CAGR) of 12.3% over the forecast period, highlighting the increasing commercial viability of fusion proteins.
According to a report published by ResearchAndMarkets.com, the rise in demand for fusion proteins is driving the development of biosimilar alternatives. Notable medications such as Enbrel, Orencia, Trulicity, Eylea, and Arcalyst are expected to dominate sales in 2024.
This comprehensive report provides an in-depth analysis of global market trends, encompassing revenue figures from 2024 and estimates for 2025, along with forecasts extending to 2030. The market is divided into various categories, including cytokine traps, peptide-based fusion proteins, receptor-based fusion proteins, and others.
Applications for fusion proteins are segmented into areas like autoimmune diseases, metabolic disorders, hematological diseases, and ophthalmic conditions. The administration methods include intravenous, subcutaneous, and intravitreal routes, among others. Regional insights focus on key markets such as North America, Europe, and Asia-Pacific, emphasizing major countries within these regions.
The report also examines key market drivers and challenges, including environmental, social, and corporate governance (ESG) trends, along with emerging technologies. The competitive landscape is analyzed, offering insights into company profiles and market strategies, particularly concerning Fc-fusion protein products.
Key features of the report include:
- 92 data tables and 51 supplementary tables, providing a detailed overview.
- Historical market data analysis from 2022 to 2024, with projections through 2030.
- Market size and growth forecasts, including detailed market share analyses across different segments.
- Examination of market dynamics, regulatory impacts, and macroeconomic factors.
- Assessment of U.S. tariff legislation and the influence of AI on the fusion proteins market.
- Utilization of Porter”s Five Forces model, complemented by global supply chain analyses.
- Insights into diagnostics and research industry trends, ongoing research, new product approvals, and relevant clinical trials.
- Identification of leading industry players and scrutiny of the competitive landscape.
- Analysis of ESG trends, focusing on consumer perceptions, practices, and risk assessments.
- A thorough patent analysis featuring significant granted and published patents.
- Overview of industry structure, including market share rankings and strategic initiatives from companies.
This report serves as a crucial resource for stakeholders in the fusion proteins market, providing vital information to navigate the evolving landscape of this rapidly growing sector.
